Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's diseaseSCIENCE TRANSLATIONAL MEDICINEIF14.62021-05-1260PRE
Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy VolunteersADVANCES IN THERAPYIF42021-03-292OAAI
ETROLIZUMAB TREATMENT MODULATES SOLUBLE MADCAM-1 LEVELS IN SERUM IN PATIENTS WITH CROHN'S DISEASEGASTROENTEROLOGYIF25.12019-02-010PREAI
Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352AAAPS JOURNALIF3.72018-12-137PREAI
Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL-22Fc): A Potential Therapy for Epithelial InjuryCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52018-08-1256OA
Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel diseaseALIMENTARY PHARMACOLOGY & THERAPEUTICSIF6.72018-03-3037OAAI
Nasal Biomarkers Characterization In Lebrikizumab Bronchoscopy Study (CLAVIER)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22018-02-012PREAI
REG3A IS INDUCED IN RESPONSE TO IL-22 AND CORRELATED WITH PERIPHERAL IL-22 LEVELS IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASEGASTROENTEROLOGYIF25.12017-04-010PREAI
Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case studyMABSIF7.32014-11-0311OAAI
A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytesBRITISH JOURNAL OF PHARMACOLOGYIF7.72011-03-2286OAAI
Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinomaJOURNAL OF PATHOLOGYIF5.22009-03-3067PREAI